PipelineNovel compounds being developed for liver diseases
Intercept’s lead product, OCALIVA® (obeticholic acid), was granted accelerated approval by U.S. Food and Drug Administration (FDA) in May of 2016 for the treatment of primary biliary cholangitis, previously known as primary biliary cirrhosis (PBC), in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA. OCALIVA is the first PBC therapy that targets the farnesoid X receptor (FXR), a key regulator of bile acid, inflammatory, fibrotic and metabolic pathways. For more information, please visit ocaliva.com.
Obeticholic acid (OCA) is also being evaluated for potential indications across a variety of additional chronic liver diseases, including nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), and biliary atresia.
The pipeline chart below shows the target indications and current stages of development of all of our product candidates.
*Formerly known as primary biliary cirrhosis.
Investigators interested in consideration for possible clinical trial participation should email ICPTinvestigators@interceptpharma.com.
You are now being directed to Intercept’s clinician survey site, hosted by FluidSurveys.